title: Mixed connective tissue disease with multiple organ damage: successful treatment with plasmapheresis.
abstract: A 24-year-old-woman with mixed connective tissue disease (MCTD) developed multiple organ failure, disseminated intravascular coagulation (DIC), metabolic acidosis, and respiratory and renal failure resulting from visceral vasospasm, so-called visceral Raynaud's phenomenon. After plasmapheresis, the condition of multiple organ failure was markedly improved. The successful treatment with plasmapheresis was dependent upon the removal of immune complexes in serum and improvement of visceral circulation. Thus plasma exchange is recommended as a possible a treatment for multiple organ damage in MCTD.
authors.affiliation: Total Care Unit, Yamaguchi University School of Medicine, Ube.
authors.forename: M
authors.initials: M
authors.lastname: Seguchi
authors.forename: Y
authors.initials: Y
authors.lastname: Soejima
authors.forename: A
authors.initials: A
authors.lastname: Tateishi
authors.forename: H
authors.initials: H
authors.lastname: Iida
authors.forename: M
authors.initials: M
authors.lastname: Yamamoto
authors.forename: K
authors.initials: K
authors.lastname: Nakashima
authors.forename: F
authors.initials: F
authors.lastname: Murakami
authors.forename: S
authors.initials: S
authors.lastname: Ohashi
authors.forename: S
authors.initials: S
authors.lastname: Yamashita
authors.forename: T
authors.initials: T
authors.lastname: Maekawa
authors.forename: A
authors.initials: A
authors.lastname: Murashige
authors.forename: S
authors.initials: S
authors.lastname: Umemoto
authors.forename: M
authors.initials: M
authors.lastname: Matsuzaki
authors.forename: Y
authors.initials: Y
authors.lastname: Fukumoto
mesh_terms: D000138:Acidosis / Q000209:etiology; D000328:Adult; D001324:Autoantigens / Q000276:immunology; D001327:Autoimmune Diseases / Q000150:complications / Q000473:pathology / Q000628:therapy*; D001991:Bronchitis / Q000209:etiology; D002114:Calcinosis / Q000209:etiology; D003131:Combined Modality Therapy; D016572:Cyclosporine / Q000627:therapeutic use; D004211:Disseminated Intravascular Coagulation / Q000209:etiology; D005260:Female; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007511:Ischemia / Q000209:etiology*; D008775:Methylprednisolone / Q000627:therapeutic use; D008947:Mixed Connective Tissue Disease / Q000150:complications / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D009102:Multiple Organ Failure / Q000209:etiology* / Q000628:therapy; D010956:Plasmapheresis; D017412:Ribonucleoprotein, U1 Small Nuclear / Q000276:immunology; D014661:Vasoconstriction; D014781:Viscera / Q000098:blood supply
chemical_list: D001324:Autoantigens; D007166:Immunosuppressive Agents; D017412:Ribonucleoprotein, U1 Small Nuclear; D016572:Cyclosporine; D008775:Methylprednisolone